Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 6, 2022 (5 years ago)

Losartan Potassium 50 mg Tablet

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Losartan Potassium 50 mg Tablet, a) 30-count blister card (NDC# 70518-3282-1), b) 60-count blister card (NDC: 70518-3282-0), Rx Only, MFG by: Lupin Pharma, Baltimore, MD 21202.

Affected NDCs 70518-3282-00 70518-3282-01

Compare with the code on your package — it is the most precise check available.

Drug: Losartan Category: Blood Pressure Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Losartan Potassium
NDC 70518-3282
50 mg/1 Tablet
Oral
Remedyrepack INC. Rx
Recalling firm
RemedyRepack Inc.
NDC code
70518-3282-1
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0788-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Losartan recalls

See all

Other recalls by RemedyRepack Inc.

All 2022 recalls
Class II · Moderate risk

Clindamycin HCl Capsule

CGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets.

Ongoing cGMP deviation RemedyRePack Inc. D-0411-2025
Class II · Moderate risk

Carvedilol 25 mg Tablet

CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.

Terminated Nitrosamine impurity RemedyRepack Inc. D-0217-2025